In last trading session, Travere Therapeutics Inc (NASDAQ:TVTX) saw 0.82 million shares changing hands with its beta currently measuring 0.70. Company’s recent per share price level of $6.16 trading at $0.16 or 2.67% at ring of the bell on the day assigns it a market valuation of $468.78M. That closing price of TVTX’s stock is at a discount of -217.21% from its 52-week high price of $19.54 and is indicating a premium of 16.88% from its 52-week low price of $5.12. Taking a look at company’s average trading volume volume of 1.22 million if we extend that period to 3-months.
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Upright in the green during last session for gaining 2.67%, in the last five days TVTX remained trading in the green while hitting it’s week-highest on Thursday, 05/02/24 when the stock touched $6.16 price level, adding 0.65% to its value on the day. Travere Therapeutics Inc’s shares saw a change of -31.48% in year-to-date performance and have moved 14.29% in past 5-day. Travere Therapeutics Inc (NASDAQ:TVTX) showed a performance of -11.75% in past 30-days.
Travere Therapeutics Inc (TVTX) estimates and forecasts
Statistics highlight that Travere Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -4.94% of value to its shares in past 6 months, showing an annual growth rate of 38.86% while that of industry is 12.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 48.60% from the last financial year’s standing.
13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 42.85M for the same. And 13 analysts are in estimates of company making revenue of 53.29M in the next quarter. Company posted 56.99M and 59.7M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -12.34% during past 5 years.
TVTX Dividends
Travere Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
